Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 5;31(5):107601.
doi: 10.1016/j.celrep.2020.107601.

Srebf1 Controls Midbrain Dopaminergic Neurogenesis

Affiliations
Free article

Srebf1 Controls Midbrain Dopaminergic Neurogenesis

Enrique M Toledo et al. Cell Rep. .
Free article

Abstract

Liver X receptors (LXRs) and their ligands are potent regulators of midbrain dopaminergic (mDA) neurogenesis and differentiation. However, the molecular mechanisms by which LXRs control these functions remain to be elucidated. Here, we perform a combined transcriptome and chromatin immunoprecipitation sequencing (ChIP-seq) analysis of midbrain cells after LXR activation, followed by bioinformatic analysis to elucidate the transcriptional networks controlling mDA neurogenesis. Our results identify the basic helix-loop-helix transcription factor sterol regulatory element binding protein 1 (SREBP1) as part of a cluster of proneural transcription factors in radial glia and as a regulator of transcription factors controlling mDA neurogenesis, such as Foxa2. Moreover, loss- and gain-of-function experiments in vitro and in vivo demonstrate that Srebf1 is both required and sufficient for mDA neurogenesis. Our data, thus, identify Srebf1 as a central player in mDA neurogenesis.

Keywords: FOXA2; LXR; Parkinson disease; bHLH; chromatin immunoprecipitation; development; nuclear receptor; oxysterol; radial glia; single-cell RNA sequencing; transcriptional network.

PubMed Disclaimer

Conflict of interest statement

Declaration of Interests E.A. is a founder and shareholder of Cholestenix, Ltd. Patent applications by E.A. in this area: WO 2014/132052 and WO 2015/036726.

Publication types

MeSH terms

Substances

LinkOut - more resources